

Pierre Ernst

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2386493/publications.pdf>

Version: 2024-02-01

87
papers

4,387
citations

136740

32
h-index

106150

65
g-index

87
all docs

87
docs citations

87
times ranked

4340
citing authors

#	ARTICLE	IF	CITATIONS
1	Triple Inhaler versus Dual Bronchodilator Therapy in COPD: Real-World Effectiveness on Mortality. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2022, 19, 1-9.	0.7	19
2	Fluticasone-Based versus Budesonide-Based Triple Therapies in COPD: Real-World Comparative Effectiveness and Safety. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2022, 19, 109-117.	0.7	3
3	Discontinuation of Inhaled Corticosteroids from Triple Therapy in COPD: Effects on Major Outcomes in Real World Clinical Practice. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2022, 19, 133-141.	0.7	4
4	A multifaceted intervention to improve asthma control via asthma education, medical follow-up and regular self-monitoring after pediatric emergency department visits for asthma. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2021, 5, 28-37.	0.2	0
5	Effectiveness of Proton Pump Inhibitors in Idiopathic Pulmonary Fibrosis. Chest, 2021, 159, 673-682.	0.4	31
6	Type 2 diabetes mellitus and risk of community-acquired pneumonia: a systematic review and meta-analysis of observational studies. CMAJ Open, 2021, 9, E62-E70.	1.1	14
7	SGLT 2 inhibitors and the risk of hospitalization for community-acquired pneumonia: A population-based cohort study. Pharmacoepidemiology and Drug Safety, 2021, 30, 740-748.	0.9	6
8	Comparative Effectiveness of Initial LAMA versus LABA in COPD: Real-World Cohort Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2021, 18, 1-8.	0.7	11
9	Validity of an algorithm to identify cardiovascular deaths from administrative health records: a multi-database population-based cohort study. BMC Health Services Research, 2021, 21, 758.	0.9	8
10	Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple population-based cohort studies. Pharmacoepidemiology and Drug Safety, 2021, 30, 1339-1352.	0.9	17
11	Regional variation in the potentially inappropriate first-line use of fluoroquinolones in Canada as a key to antibiotic stewardship? A drug utilization review study. BMC Infectious Diseases, 2021, 21, 733.	1.3	4
12	Comparing initial LABA-ICS inhalers in COPD: Real-world effectiveness and safety. Respiratory Medicine, 2021, 189, 106645.	1.3	7
13	Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study. Rheumatology, 2020, 59, 820-827.	0.9	5
14	Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD. Chest, 2020, 157, 846-855.	0.4	57
15	Inhaled corticosteroid use and the incidence of lung cancer in COPD. European Respiratory Journal, 2020, 55, 1901720.	3.1	18
16	Response. Chest, 2020, 158, 832-833.	0.4	0
17	Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis. Annals of Internal Medicine, 2020, 173, 417-425.	2.0	97
18	Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study. Diabetes Care, 2020, 43, 2444-2452.	4.3	26

#	ARTICLE	IF	CITATIONS
19	Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study. <i>BMJ, The</i> , 2020, 370, m3342.	3.0	70
20	Response. <i>Chest</i> , 2020, 157, 1395-1396.	0.4	0
21	Sodium-glucose co-transporter-2 inhibitors and the risk of urosepsis: A multi-site, prevalent new-user cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1648-1658.	2.2	13
22	Avoiding immortal time bias in observational studies. <i>European Respiratory Journal</i> , 2020, 55, 2000138.	3.1	5
23	Response. <i>Chest</i> , 2020, 157, 1045-1046.	0.4	0
24	Response. <i>Chest</i> , 2019, 156, 416-417.	0.4	0
25	Comparative safety of abatacept in rheumatoid arthritis with COPD: A real-world population-based observational study. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 366-372.	1.6	12
26	Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in Real-World Clinical Practice. <i>Chest</i> , 2019, 155, 1158-1165.	0.4	58
27	Comparative Effectiveness Of Fluoroquinolone Antibiotic Use In Uncomplicated Acute Exacerbations Of COPD: A Multi-Cohort Study. <i>International Journal of COPD</i> , 2019, Volume 14, 2939-2946.	0.9	5
28	Observational Studies of Inhaled Corticosteroid Effectiveness in COPD. <i>Chest</i> , 2018, 154, 257-265.	0.4	23
29	Long-term Use of Inhaled Corticosteroids in COPD and the Risk of Fracture. <i>Chest</i> , 2018, 153, 321-328.	0.4	55
30	Beta-Blockers in COPD: A Methodological Review of the Observational Studies. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2018, 15, 520-525.	0.7	10
31	Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. <i>Lancet Respiratory Medicine</i> , 2018, 6, 855-862.	5.2	79
32	Blood eosinophils in COPD and the future risk of pneumonia. <i>European Respiratory Journal</i> , 2018, 52, 1800981.	3.1	9
33	Pneumonia risk in asthma patients using inhaled corticosteroids: a quasi-cohort study. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2077-2086.	1.1	45
34	Androgen deprivation therapy for prostate cancer and the risk of hospitalisation for community-acquired pneumonia. <i>Thorax</i> , 2017, 72, 596.1-597.	2.7	8
35	Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. <i>European Respiratory Journal</i> , 2017, 49, 1602245.	3.1	65
36	The Risk of Sepsis with Inhaled and Oral Corticosteroids in Patients with COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 137-142.	0.7	15

#	ARTICLE	IF	CITATIONS
37	Statin potency and the risk of hospitalization for community-acquired pneumonia. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1319-1327.	1.1	9
38	Enablers and determinants of the provision of written action plans to patients with asthma: a stratified survey of Canadian physicians. <i>Npj Primary Care Respiratory Medicine</i> , 2017, 27, 21.	1.1	23
39	Precision Medicine Urgency. <i>Chest</i> , 2017, 152, 227-231.	0.4	29
40	Physician agreement regarding the expansion of pharmacist professional activities in the management of patients with asthma. <i>International Journal of Pharmacy Practice</i> , 2017, 25, 335-342.	0.3	5
41	Long-Acting Bronchodilator Initiation in COPD and the Risk of Adverse Cardiopulmonary Events. <i>Chest</i> , 2017, 151, 60-67.	0.4	41
42	The effect of statins on influenza-like illness morbidity and mortality. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 63-70.	0.9	17
43	Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study. <i>BMJ: British Medical Journal</i> , 2017, 359, j4323.	2.4	77
44	Enablers of Physician Prescription of a Long-Term Asthma Controller in Patients with Persistent Asthma. <i>Canadian Respiratory Journal</i> , 2016, 2016, 1-9.	0.8	5
45	Confounding by drug formulary restriction in pharmacoepidemiologic research. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 278-286.	0.9	6
46	Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 461-472.	1.1	35
47	The INPULSIS trials of idiopathic pulmonary fibrosis treatment: explaining further discrepancies on exacerbations. <i>European Respiratory Journal</i> , 2016, 47, 344-345.	3.1	3
48	A Multicenter Observational Study of Incretin-based Drugs and Heart Failure. <i>New England Journal of Medicine</i> , 2016, 374, 1145-1154.	13.9	191
49	Inflammatory bowel disease and risk of mortality in COPD. <i>European Respiratory Journal</i> , 2016, 47, 1357-1364.	3.1	29
50	Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. <i>BMJ</i> , 2016, 352, i581.	3.0	78
51	The Effectiveness of Web-Based Asthma Self-Management System, My Asthma Portal (MAP): A Pilot Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2016, 18, e313.	2.1	59
52	Phenotypic Heterogeneity of Potentially Curable Non-Small-Cell Lung Cancer: Cohort Study with Cluster Analysis. <i>Journal of Thoracic Oncology</i> , 2015, 10, 754-761.	0.5	9
53	Tailoring interventions: identifying predictors of poor asthma control. <i>Annals of Allergy, Asthma and Immunology</i> , 2015, 114, 485-491.e1.	0.5	3
54	Discontinuation of Inhaled Corticosteroids in COPD and the Risk Reduction of Pneumonia. <i>Chest</i> , 2015, 148, 1177-1183.	0.4	68

#	ARTICLE	IF	CITATIONS
55	The INPULSIS enigma: exacerbations in idiopathic pulmonary fibrosis. <i>Thorax</i> , 2015, 70, 508-510.	2.7	14
56	Inhaled corticosteroids in COPD: the clinical evidence. <i>European Respiratory Journal</i> , 2015, 45, 525-537.	3.1	148
57	Long-Acting $\hat{1}^2$ -Agonists With vs Without Inhaled Corticosteroids for COPD. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 305.	3.8	2
58	Patients's perspective of barriers and facilitators to taking long-term controller medication for asthma: a novel taxonomy. <i>BMC Pulmonary Medicine</i> , 2015, 15, 42.	0.8	63
59	Evaluating the impact of an integrated computer-based decision support with person-centered analytics for the management of asthma in primary care: a randomized controlled trial. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2015, 22, 773-783.	2.2	26
60	Increased incidence of inflammatory bowel disease in Qu'bec residents with airway diseases. <i>European Respiratory Journal</i> , 2015, 45, 962-968.	3.1	50
61	Friday and weekend hospital stays: effects on mortality. <i>European Respiratory Journal</i> , 2014, 44, 627-633.	3.1	14
62	Inhaled corticosteroids in COPD and the risk of serious pneumonia. <i>Thorax</i> , 2013, 68, 1029-1036.	2.7	383
63	Educating the Adolescent and Young Adult With Cystic Fibrosis About Their Reproductive Risks and Options: Response. <i>Chest</i> , 2013, 143, 580.	0.4	1
64	Systemic effects of inhaled corticosteroids. <i>Current Opinion in Pulmonary Medicine</i> , 2012, 18, 85-89.	1.2	36
65	Bronchodilator Use and the Risk of Arrhythmia in COPD. <i>Chest</i> , 2012, 142, 298-304.	0.4	49
66	Bronchodilator Use and the Risk of Arrhythmia in COPD. <i>Chest</i> , 2012, 142, 305-311.	0.4	87
67	Pramipexole use and the risk of pneumonia. <i>BMC Neurology</i> , 2012, 12, 113.	0.8	5
68	CNODES: the Canadian Network for Observational Drug Effect Studies. <i>Open Medicine</i> , 2012, 6, e134-40.	1.5	52
69	Risk of herpes zoster in patients prescribed inhaled corticosteroids: a cohort study. <i>BMC Pulmonary Medicine</i> , 2011, 11, 59.	0.8	16
70	Effect of a web-based chronic disease management system on asthma control and health-related quality of life: study protocol for a randomized controlled trial. <i>Trials</i> , 2011, 12, 260.	0.7	27
71	<i>The Asthma Quiz for Kidz</i>: A Validated Tool to Appreciate the Level of Asthma Control in Children. <i>Canadian Respiratory Journal</i> , 2004, 11, 541-546.	0.8	34
72	What Is New Since the Last (1999) Canadian Asthma Consensus Guidelines?. <i>Canadian Respiratory Journal</i> , 2001, 8, 5A-27A.	0.8	73

#	ARTICLE	IF	CITATIONS
73	Control of Asthma in Canada: Failure to Achieve Guideline Targets. Canadian Respiratory Journal, 2001, 8, 35A-40A.	0.8	124
74	Prostaglandin H Synthase 2 Expression in Airway Cells from Patients with Asthma and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 636-640.	2.5	84
75	Inhaled Drug Delivery: A Practical Guide to Prescribing Inhaler Devices. Canadian Respiratory Journal, 1998, 5, 180-183.	0.8	23
76	Increased Expression of Interleukin-16 in Bronchial Mucosa of Subjects with Atopic Asthma. American Journal of Respiratory Cell and Molecular Biology, 1997, 17, 193-202.	1.4	141
77	Birthweight and Preterm Birth in Relation to Indicators of Childhood Asthma. Canadian Respiratory Journal, 1997, 4, 91-97.	0.8	8
78	Use of Oral Xanthines in the Elderly and Extent of "Silent Risks": Information from a Drug Dispensing Database. , 1997, 6, 135-136.		0
79	Confounding by Indication and Channeling over Time: The Risks of β_2 -Agonists. American Journal of Epidemiology, 1996, 144, 1161-1169.	1.6	100
80	Increased morbidity and mortality related to asthma among asthmatic patients who use major tranquilisers. BMJ: British Medical Journal, 1996, 312, 79-81.	2.4	63
81	What Is the Role of Beta-Agonist Bronchodilators in the Day-to-Day Treatment of Chronic Asthma?. Canadian Respiratory Journal, 1995, 2, 32A-34A.	0.8	0
82	The Use of β_2 -Agonists and the Risk of Death and near Death from Asthma. New England Journal of Medicine, 1992, 326, 501-506.	13.9	1,228
83	Fenoterol and death from asthma. Medical Journal of Australia, 1992, 157, 567-568.	0.8	2
84	Fissural thickening and exposure to asbestos: Occurrence, determinants, and functional impact. American Journal of Industrial Medicine, 1991, 20, 785-793.	1.0	3
85	Relationship of lung geometry to the development of pleural abnormalities in insulation workers exposed to asbestos. American Journal of Industrial Medicine, 1989, 15, 417-425.	1.0	3
86	Obstructive and restrictive ventilatory impairment in polyvinylchloride fabrication workers. American Journal of Industrial Medicine, 1988, 14, 273-279.	1.0	10
87	Between- and within-reader variability in the assessment of pleural abnormality using the ILO 1980 international classification of pneumoconioses. American Journal of Industrial Medicine, 1988, 14, 537-543.	1.0	32